Mass. Biotech Biz Gets PTAB To Wipe Alzheimer's Drug Patent
By Andrew Karpan ( July 13, 2022, 5:10 PM EDT) -- A panel of Patent Trial and Appeal Board judges has sided with arguments from Boston biotech developer Alzheon Inc. that the patent office never should have granted a patent to a smaller Chinese rival that covers a way of using a type of sulfonic acid to potentially treat Alzheimer's disease....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.